The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

被引:1552
作者
Younossi, Zobair M. [1 ,2 ,3 ]
Golabi, Pegah [1 ,2 ,3 ]
Paik, James M. [1 ,2 ,3 ]
Henry, Austin [1 ]
Van Dongen, Catherine [1 ]
Henry, Linda [1 ,2 ,3 ]
机构
[1] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA USA
[2] Inova Fairfax Med Campus, Ctr Liver Dis, Dept Med, Falls Church, VA USA
[3] Inova Hlth Syst, Inova Med, Falls Church, VA USA
关键词
PREVALENCE; METAANALYSIS; REGRESSION; BURDEN; UPDATE; BIAS;
D O I
10.1097/HEP.0000000000000004
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims: NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an in-depth meta-analytic approach. Approach and Results: PubMed and Ovid MEDLINE were searched for NAFLD population-based studies from 1990 to 2019 survey year (last published 2022) per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Meta-analysis was conducted using randomeffects models. Bias risk assessment was per Joanna Briggs Institute. Of 2585 studies reviewed, 92 studies (N = 9,361,716) met eligibility criteria. Across the study period (1990-2019), meta-analytic pooling of NAFLD prevalence estimates and ultrasound-defined NAFLD yielded an overall global prevalence of 30.05% (95% CI: 27.88%-32.32%) and 30.69% (28.4-33.09), respectively. Global NAFLD prevalence increased by +50.4% from 25.26% (21.59-29.33) in 1990-2006 to 38.00% (33.71-42.49) in 2016-2019 (p<0.001); ultrasound-defined NAFLD prevalence increased by +38.7% from 25.16% (19.46-31.87) in 1990-2006 to 34.59% (29.05-40.57) (p = 0.029). The highest NAFLD prevalence was in Latin America 44.37% (30.66%-59.00%), then Middle East and North Africa (MENA) (36.53%, 28.63%-45.22%), South Asia (33.83%, 22.91%-46.79%), South-East Asia (33.07%, 18.99%-51.03%), North America (31.20%, 25.86%-37.08%), East Asia (29.71%, 25.96%-33.76%), Asia Pacific 28.02% (24.69%-31.60%), Western Europe 25.10% (20.55%-30.28%). Among the NAFLD cohort diagnosed without a liver biopsy, pooled mortality rate per 1000 PY was 12.60 (6.68-23.67) for all-cause mortality; 4.20 (1.34-7.05) for cardiac-specific mortality; 2.83 (0.78-4.88) for extrahepatic cancer-specific mortality; and 0.92 (0.00-2.21) for liver-specific mortality. Conclusions: NAFLD global prevalence is 30% and increasing which requires urgent and comprehensive strategies to raise awareness and address all aspects of NAFLD on local, regional, and global levels.
引用
收藏
页码:1335 / 1347
页数:13
相关论文
共 41 条
[1]  
[Anonymous], 2022, Global Burden of Disease Study 2019 Results
[2]  
[Anonymous], 2012, World Health Day
[3]  
[Anonymous], Global Burden of Disease (GBD)
[4]   A RANDOM-EFFECTS REGRESSION-MODEL FOR METAANALYSIS [J].
BERKEY, CS ;
HOAGLIN, DC ;
MOSTELLER, F ;
COLDITZ, GA .
STATISTICS IN MEDICINE, 1995, 14 (04) :395-411
[6]   Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications [J].
Cusi, Kenneth .
GASTROENTEROLOGY, 2012, 142 (04) :711-U109
[7]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188
[8]   Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States [J].
Doycheva, Iliana ;
Issa, Danny ;
Watt, Kymberly D. ;
Lopez, Rocio ;
Rifai, Ghassoub ;
Alkhouri, Naim .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2018, 52 (04) :339-346
[9]  
easl, Accessible lay summary on fighting fatty liver disease
[10]   Bias in meta-analysis detected by a simple, graphical test [J].
Egger, M ;
Smith, GD ;
Schneider, M ;
Minder, C .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :629-634